Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.
Amniotic epithelial cells from the human placenta potently suppress a mouse model of multiple sclerosis.
Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply.
Impact of acupuncture by using life-energy (qi) oriental needle on the paralysis of rats with experimental autoimmune encephalomyelitis.
Dual-Task Assessment in Natalizumab-Treated Multiple Sclerosis Patients.
Impact of Clear, Loud and Slow Speech on Scaled Intelligibility and Speech Severity in Parkinson's Disease and Multiple Sclerosis.
What to expect after natalizumab cessation in a real-life setting.
Gray matter involvement in multiple sclerosis.
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination.
Center for Drug Evaluation and Research Approval Letter, application number: 21-897
The Alice in Wonderland syndrome: an unusual in acute disseminated encephalomyelitis.
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis.
Immunomodulators for multiple sclerosis may ameliorate spinal bone loss.
1st International Symposium on Gait and Balance in MS: Gait and Balance Measures in the Evaluation of People with MS.
dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis.
Diffusion tensor imaging of acute inflammatory lesion evolution in multiple sclerosis.
A comparative study of CSF neurofilament light and heavy chain protein in MS.
A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1).
First patient enrolled in third Phase III study of oral laquinimod for relapsing-remitting multiple sclerosis
Bioinformatics challenges for genome-wide association studies.
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.
Abnormal Baseline Brain Activity in Patients with Multiple Sclerosis With Simple Spinal Cord Involvement Detected by Resting-State Functional Magnetic Resonance Imaging.
Central nervous system myeloid cells as drug targets: current status and translational challenges.
Smoking and Risk of Multiple Sclerosis: Evidence of Modification by NAT1 Variants.

Pages